本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议。5月8日晚,再鼎医药披露的2025年一季报,注定会让很多投资者“互道珍重”。尽管再鼎医药一季度总营收同比增长22%至1.065亿美元,且经营亏损大幅收窄,但明星产品艾加莫德营收的环比失速,却仍让很多投资者惊出一身冷汗。不过,Q1财报公布后,再鼎医药在港美股表现均不错,不仅没有下跌,还出现了明显的上涨。显然市场没有被艾加莫德的“短期波动...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.